According to a survey conducted in 2021, 94 percent of oncologists indicated being very or somewhat familiar with biosimilars. The percentage of physicians who are "very familiar" with biosimilars was highest among diabetes specialists.
Familiarity with biosimilars among specialized physicians in the U.S. as of 2021
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Amgen. (October 31, 2022). Familiarity with biosimilars among specialized physicians in the U.S. as of 2021 [Graph]. In Statista. Retrieved July 22, 2024, from https://www.statista.com/statistics/1088408/physicians-biosimilars-familiarity-us/
Amgen. "Familiarity with biosimilars among specialized physicians in the U.S. as of 2021." Chart. October 31, 2022. Statista. Accessed July 22, 2024. https://www.statista.com/statistics/1088408/physicians-biosimilars-familiarity-us/
Amgen. (2022). Familiarity with biosimilars among specialized physicians in the U.S. as of 2021. Statista. Statista Inc.. Accessed: July 22, 2024. https://www.statista.com/statistics/1088408/physicians-biosimilars-familiarity-us/
Amgen. "Familiarity with Biosimilars among Specialized Physicians in The U.S. as of 2021." Statista, Statista Inc., 31 Oct 2022, https://www.statista.com/statistics/1088408/physicians-biosimilars-familiarity-us/
Amgen, Familiarity with biosimilars among specialized physicians in the U.S. as of 2021 Statista, https://www.statista.com/statistics/1088408/physicians-biosimilars-familiarity-us/ (last visited July 22, 2024)
Familiarity with biosimilars among specialized physicians in the U.S. as of 2021 [Graph], Amgen, October 31, 2022. [Online]. Available: https://www.statista.com/statistics/1088408/physicians-biosimilars-familiarity-us/
